BrainStorm Cell Therapeutics Inc. is a clinical stage biotechnological company developing innovative, adult stem cell therapeutic products, derived from autologous bone marrow cells, for the treatment of highly debilitating neurodegenerative disorders. The company s current primary targets are Amyotrophic Lateral Sclerosis ALS, also known as Lou Gehrig s disease and Parkinson s disease PD . These devastating diseases have no treatment options and as such represent highly unmet medical needs. Upon completion of BrainStorm s clinical trials program and regulatory approvals, this novel therapy will provide compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By redirecting the inherent regenerative capacities of adult stem cells towards treating the basic disease pathologies, BrainStorm will enable healthcare institutions and society at large to realize massive savings in treatment and care costs. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
Quote | Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Last: | $0.3424 |
---|---|
Change Percent: | 0.03% |
Open: | $0.3529 |
Close: | $0.3424 |
High: | $0.3674 |
Low: | $0.3303 |
Volume: | 138,076 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire A conference call and webcast will be held Monday, July 8 , at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeut...
2024-06-27 09:51:12 ET More on BrainStorm Cell Therapeutics BrainStorm appoints Haro Hartounian as COO BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical ear...
Message Board Posts | Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $BCLI News Article - BrainStorm Cell Therapeutics Strengthens Leadership Team with Appo | whytestocks | investorshangout | 04/24/2023 12:25:46 PM |
Our valuation remains at $20 per share. | midastouch017 | investorshub | 04/06/2023 5:24:37 AM |
From Zacks: | Fmello | investorshub | 04/04/2023 8:46:30 PM |
https://www.neurologylive.com/view/critical-importance-fda-adcomm-meeting-als-th | Fmello | investorshub | 04/03/2023 8:50:04 PM |
$BCLI stock rose 80.33% in five days! | Fmello | investorshub | 04/01/2023 3:46:34 PM |
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire A conference call and webcast will be held Monday, July 8 , at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeut...
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics fo...
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial PR Newswire NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell thera...